SER

SEC source: 0001708599-25-000071 · wk-form4_1752763244.xml · nonDerivative · entry 2

Moreadith Randall · CIK 0001301120 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.91. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

SEC source: 0001708599-25-000071 · wk-form4_1752763244.xml · nonDerivative · entry 1

Moreadith Randall · CIK 0001301120 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001708599-25-000069 · wk-form4_1752072457.xml · derivative · entry 3

Moreadith Randall · CIK 0001301120 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 508,186

Underlying: Common Stock · 6,500 shares

Expires 2031-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock options are fully vested.

SEC source: 0001708599-25-000069 · wk-form4_1752072457.xml · nonDerivative · entry 2

Moreadith Randall · CIK 0001301120 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.55 to $5.94. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

SEC source: 0001708599-25-000069 · wk-form4_1752072457.xml · nonDerivative · entry 1

Moreadith Randall · CIK 0001301120 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001708599-25-000067 · wk-form4_1751468419.xml · derivative · entry 3

Moreadith Randall · CIK 0001301120 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 514,686

Underlying: Common Stock · 6,500 shares

Expires 2031-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock options are fully vested.

SEC source: 0001708599-25-000067 · wk-form4_1751468419.xml · nonDerivative · entry 2

Moreadith Randall · CIK 0001301120 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.68 to $6.05. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

SEC source: 0001708599-25-000067 · wk-form4_1751468419.xml · nonDerivative · entry 1

Moreadith Randall · CIK 0001301120 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001708599-25-000063 · wk-form4_1750206999.xml · derivative · entry 1

Brannan Stephen K. · CIK 0001777631 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2035-05-22

F1 · derivative.exercise_date: The stock options vest in substantially equal yearly installments beginning on the aniversary of the grant date such that the stock options shall be fully vested on the third anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

SEC source: 0001708599-25-000038 · wk-form4_1744315385.xml · derivative · entry 1

Venkatesan Jay · CIK 0001413350 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · The Jay Venkatesan Legacy Trust

Disclosed balance after: 96,525

Underlying: Common Stock, $0.0001 par value · 96,525 shares

Expires not disclosed

F1 · derivative.expiration_date: The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date.

SEC source: 0001708599-25-000037 · wk-form4_1744315352.xml · derivative · entry 1

Bailey Gregory · CIK 0001329505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 762,548

Underlying: Common Stock, $0.0001 par value · 762,548 shares

Expires not disclosed

F1 · derivative.expiration_date: The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date.

SEC source: 0001628280-25-015888 · wk-form4_1743537960.xml · nonDerivative · entry 1

LEDGER STEVEN A · CIK 0001090206 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,730

F1 · kind: Pro rata distribution from Ki Partners LLC, of which the Reporting Person is a manager.

F2 · balance_after: In prior reports, the Reporting Person reported beneficial ownership of 227,927 shares of the Issuers common stock held by Ki Partners LLC.

SEC source: 0001708599-25-000021 · wk-form4_1739484224.xml · derivative · entry 1

Venkatesan Jay · CIK 0001413350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2035-02-12

F1 · derivative.exercise_date: The stock options vest in substantially equal yearly installments beginning on the first anniversary of the grant date such that the stock options shall be fully vested on the third anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

SEC source: 0001104659-25-008610 · tm255065-1_4seq1.xml · derivative · entry 8

Juvenescence Ltd · CIK 0001724307 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Juv UK

Disclosed balance after: 755,728

Underlying: Common Stock · 377,864 shares

Expires not disclosed

F3 · derivative.exercise_price: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants.

F3 · price: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants.

F3 · derivative.exercise_date: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants.

F3 · derivative.expiration_date: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants.

SEC source: 0001104659-25-008610 · tm255065-1_4seq1.xml · nonDerivative · entry 3

Juvenescence Ltd · CIK 0001724307 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · Bu Juv UK

Disclosed balance after: 3,267,188

F1 · balance_after: As previously reported, on March 26, 2024, the Issuer (formerly known as "AgeX Therapeutics, Inc.") completed its merger transaction with, inter alia, Serina Therapeutics, Inc. (the "Merger"). Following the closing of the Merger, the Reporting Person held 1,889,323 shares of the Issuer's common stock, which shares are included in Column 5. These shares are held by the Reporting Person's wholly owned subsidiary, JuvVentures (UK) ("Juv UK"). Additional details about the Merger and the transactions described in this report can be found in the Issuer's and the Reporting Person's previous filings with the Commission.

F3 · balance_after: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants.

SEC source: 0001708599-25-000009 · wk-form4_1736976192.xml · derivative · entry 1

WILSON KAREN J · CIK 0001267490 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2035-01-13

F1 · derivative.exercise_date: The stock options vest in substantially equal yearly installments beginning on the first anniversary of the grant date such that the stock options shall be fully vested on the third anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

SEC source: 0001493152-24-050774 · ownership.xml · nonDerivative · entry 1

Bailey Gregory · CIK 0001329505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,243

F1 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low of $4.54 per share to a high of $4.74 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price.

SEC source: 0001104659-25-008610 · tm255065-1_4seq1.xml · derivative · entry 7

Juvenescence Ltd · CIK 0001724307 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Juv UK

Disclosed balance after: 377,864

Underlying: Common Stock · 377,864 shares

Expires not disclosed

F3 · price: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants.

F3 · derivative.exercise_date: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants.

F3 · derivative.expiration_date: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants.

SEC source: 0001104659-25-008610 · tm255065-1_4seq1.xml · derivative · entry 6

Juvenescence Ltd · CIK 0001724307 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Juv UK

Disclosed balance after: 0

Underlying: Common Stock · 755,728 shares

Expires not disclosed

F3 · price: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants.

F3 · derivative.exercise_date: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants.

F3 · derivative.expiration_date: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants.

SEC source: 0001104659-25-008610 · tm255065-1_4seq1.xml · nonDerivative · entry 2

Juvenescence Ltd · CIK 0001724307 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Juv UK

Disclosed balance after: 2,767,188

F1 · balance_after: As previously reported, on March 26, 2024, the Issuer (formerly known as "AgeX Therapeutics, Inc.") completed its merger transaction with, inter alia, Serina Therapeutics, Inc. (the "Merger"). Following the closing of the Merger, the Reporting Person held 1,889,323 shares of the Issuer's common stock, which shares are included in Column 5. These shares are held by the Reporting Person's wholly owned subsidiary, JuvVentures (UK) ("Juv UK"). Additional details about the Merger and the transactions described in this report can be found in the Issuer's and the Reporting Person's previous filings with the Commission.

F3 · balance_after: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants.

SEC source: 0001493152-24-037965 · ownership.xml · nonDerivative · entry 1

Bailey Gregory · CIK 0001329505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,377

F1 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low of $5.74 per share to a high of $6.25 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price.

SEC source: 0001493152-24-037714 · ownership.xml · nonDerivative · entry 2

Bailey Gregory · CIK 0001329505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,240

F2 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low of $5.96 per share to a high of $6.25 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price.

SEC source: 0001493152-24-037714 · ownership.xml · nonDerivative · entry 1

Bailey Gregory · CIK 0001329505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,561

F1 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low of $6.18 per share to a high of $6.25 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price.

SEC source: 0001493152-24-036461 · ownership.xml · nonDerivative · entry 1

MINTZ STEVEN · CIK 0002008741 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 17,443

F1 · price: The price reflects the weighted average purchase price of multiple transactions. Upon the written request of the SEC, the issuer or a security holder of the issuer, the Reporting Person agrees to provide the number of shares sold at each sale price.

SEC source: 0001493152-24-035804 · ownership.xml · derivative · entry 1

LEDGER STEVEN A · CIK 0001090206 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 490,350

Underlying: Common Stock · 376,388 shares

Expires 2034-09-09

F1 · derivative.exercise_date: The stock options vest as to 12.5% of the underlying shares on March 9, 2025 and thereafter in substantially equal monthly installments such that the stock options shall be fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

SEC source: 0001493152-24-033599 · ownership.xml · nonDerivative · entry 1

Bailey Gregory · CIK 0001329505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,582

F1 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low of $8.00 per share to a high of $8.88 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price.

SEC source: 0001493152-24-033277 · ownership.xml · nonDerivative · entry 3

Bailey Gregory · CIK 0001329505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,806

F3 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low of $7.24 per share to a high of $8.57 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price.

SEC source: 0001493152-24-033277 · ownership.xml · nonDerivative · entry 2

Bailey Gregory · CIK 0001329505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,406

F2 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low of $7.12 per share to a high of $8.02 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price.

SEC source: 0001493152-24-033195 · ownership.xml · nonDerivative · entry 5

MINTZ STEVEN · CIK 0002008741 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adult Child 3

Disclosed balance after: 2,650

F1 · price: The price reflects the weighted average purchase price of multiple transactions. Upon the written request of the SEC, the issuer or a security holder of the issuer, the Reporting Person agrees to provide the number of shares sold at each sale price.

F4 · ownership.nature: The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-24-033195 · ownership.xml · nonDerivative · entry 4

MINTZ STEVEN · CIK 0002008741 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adult Child 2

Disclosed balance after: 2,840

F1 · price: The price reflects the weighted average purchase price of multiple transactions. Upon the written request of the SEC, the issuer or a security holder of the issuer, the Reporting Person agrees to provide the number of shares sold at each sale price.

F3 · ownership.nature: The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-24-033195 · ownership.xml · nonDerivative · entry 3

MINTZ STEVEN · CIK 0002008741 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adult Child 1

Disclosed balance after: 3,040

F1 · price: The price reflects the weighted average purchase price of multiple transactions. Upon the written request of the SEC, the issuer or a security holder of the issuer, the Reporting Person agrees to provide the number of shares sold at each sale price.

F2 · ownership.nature: The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-24-033195 · ownership.xml · nonDerivative · entry 2

MINTZ STEVEN · CIK 0002008741 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 11,443

F1 · price: The price reflects the weighted average purchase price of multiple transactions. Upon the written request of the SEC, the issuer or a security holder of the issuer, the Reporting Person agrees to provide the number of shares sold at each sale price.

SEC source: 0001493152-24-033195 · ownership.xml · nonDerivative · entry 1

MINTZ STEVEN · CIK 0002008741 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,257

F1 · price: The price reflects the weighted average purchase price of multiple transactions. Upon the written request of the SEC, the issuer or a security holder of the issuer, the Reporting Person agrees to provide the number of shares sold at each sale price.

SEC source: 0001493152-24-033344 · ownership.xml · derivative · entry 1

CURHAN GREGORY S · CIK 0001263244 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2024-08-15

F1 · derivative.exercise_date: The stock options vest in substantially equal monthly installments beginning on September 15, 2024 such that the stock options shall be fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

SEC source: 0001493152-24-033277 · ownership.xml · nonDerivative · entry 1

Bailey Gregory · CIK 0001329505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,006

F1 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low of $6.55 per share to a high of $7.94 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price.

SEC source: 0001493152-24-032829 · ownership.xml · nonDerivative · entry 1

Bailey Gregory · CIK 0001329505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,606

F1 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low of $6.83 per share to a high of $7.35 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price.

SEC source: 0001493152-24-028205 · ownership.xml · derivative · entry 1

Tenjarla Srini · CIK 0002029985 · SVP, CMC & Formulation

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,000

Underlying: Common Stock · 185,000 shares

Expires 2034-07-15

F1 · derivative.exercise_date: The stock options vest as to 61,666 of the underlying shares on July 15, 2025, and thereafter in substantially equal installments such that the stock options shall be fully vested on the third anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

SEC source: 0001493152-24-025498 · ownership.xml · nonDerivative · entry 2

MINTZ STEVEN · CIK 0002008741 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,907

SEC source: 0001493152-24-025498 · ownership.xml · nonDerivative · entry 1

MINTZ STEVEN · CIK 0002008741 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,307

SEC source: 0001104659-25-008610 · tm255065-1_4seq1.xml · derivative · entry 5

Juvenescence Ltd · CIK 0001724307 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Juv UK

Disclosed balance after: 377,865

Underlying: Common Stock · 377,865 shares

Expires not disclosed

F2 · price: On June 6, 2024, the Reporting Person exercised 377,865 warrants at an exercise price of $13.20 per warrant (the "Original Warrants"), representing one-third of the of the Original Warrants, which were issued to the Reporting Person in connection with a warrant dividend effected on March 18, 2024, Upon such exercise, the Reporting Person was issued 377,865 shares of the Issuer's common stock and 377,865 new warrants to purchase the Issuer's common stock at an exercise price of $18.00 (the "June Warrants"). The remaining 755,728 Original Warrants were surrendered in connection with the November Agreement described in footnote 3 below. The June Warrants expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). Prior to their surrender, the Original Warrants also had an expiration date of March 26, 2028.

F2 · derivative.exercise_date: On June 6, 2024, the Reporting Person exercised 377,865 warrants at an exercise price of $13.20 per warrant (the "Original Warrants"), representing one-third of the of the Original Warrants, which were issued to the Reporting Person in connection with a warrant dividend effected on March 18, 2024, Upon such exercise, the Reporting Person was issued 377,865 shares of the Issuer's common stock and 377,865 new warrants to purchase the Issuer's common stock at an exercise price of $18.00 (the "June Warrants"). The remaining 755,728 Original Warrants were surrendered in connection with the November Agreement described in footnote 3 below. The June Warrants expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). Prior to their surrender, the Original Warrants also had an expiration date of March 26, 2028.

F2 · derivative.expiration_date: On June 6, 2024, the Reporting Person exercised 377,865 warrants at an exercise price of $13.20 per warrant (the "Original Warrants"), representing one-third of the of the Original Warrants, which were issued to the Reporting Person in connection with a warrant dividend effected on March 18, 2024, Upon such exercise, the Reporting Person was issued 377,865 shares of the Issuer's common stock and 377,865 new warrants to purchase the Issuer's common stock at an exercise price of $18.00 (the "June Warrants"). The remaining 755,728 Original Warrants were surrendered in connection with the November Agreement described in footnote 3 below. The June Warrants expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). Prior to their surrender, the Original Warrants also had an expiration date of March 26, 2028.

SEC source: 0001104659-25-008610 · tm255065-1_4seq1.xml · derivative · entry 4

Juvenescence Ltd · CIK 0001724307 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Juv UK

Disclosed balance after: 755,728

Underlying: Common Stock · 377,865 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: On June 6, 2024, the Reporting Person exercised 377,865 warrants at an exercise price of $13.20 per warrant (the "Original Warrants"), representing one-third of the of the Original Warrants, which were issued to the Reporting Person in connection with a warrant dividend effected on March 18, 2024, Upon such exercise, the Reporting Person was issued 377,865 shares of the Issuer's common stock and 377,865 new warrants to purchase the Issuer's common stock at an exercise price of $18.00 (the "June Warrants"). The remaining 755,728 Original Warrants were surrendered in connection with the November Agreement described in footnote 3 below. The June Warrants expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). Prior to their surrender, the Original Warrants also had an expiration date of March 26, 2028.

F2 · derivative.exercise_date: On June 6, 2024, the Reporting Person exercised 377,865 warrants at an exercise price of $13.20 per warrant (the "Original Warrants"), representing one-third of the of the Original Warrants, which were issued to the Reporting Person in connection with a warrant dividend effected on March 18, 2024, Upon such exercise, the Reporting Person was issued 377,865 shares of the Issuer's common stock and 377,865 new warrants to purchase the Issuer's common stock at an exercise price of $18.00 (the "June Warrants"). The remaining 755,728 Original Warrants were surrendered in connection with the November Agreement described in footnote 3 below. The June Warrants expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). Prior to their surrender, the Original Warrants also had an expiration date of March 26, 2028.

F2 · derivative.expiration_date: On June 6, 2024, the Reporting Person exercised 377,865 warrants at an exercise price of $13.20 per warrant (the "Original Warrants"), representing one-third of the of the Original Warrants, which were issued to the Reporting Person in connection with a warrant dividend effected on March 18, 2024, Upon such exercise, the Reporting Person was issued 377,865 shares of the Issuer's common stock and 377,865 new warrants to purchase the Issuer's common stock at an exercise price of $18.00 (the "June Warrants"). The remaining 755,728 Original Warrants were surrendered in connection with the November Agreement described in footnote 3 below. The June Warrants expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). Prior to their surrender, the Original Warrants also had an expiration date of March 26, 2028.

SEC source: 0001104659-25-008610 · tm255065-1_4seq1.xml · nonDerivative · entry 1

Juvenescence Ltd · CIK 0001724307 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Juv UK

Disclosed balance after: 2,267,188

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: As previously reported, on March 26, 2024, the Issuer (formerly known as "AgeX Therapeutics, Inc.") completed its merger transaction with, inter alia, Serina Therapeutics, Inc. (the "Merger"). Following the closing of the Merger, the Reporting Person held 1,889,323 shares of the Issuer's common stock, which shares are included in Column 5. These shares are held by the Reporting Person's wholly owned subsidiary, JuvVentures (UK) ("Juv UK"). Additional details about the Merger and the transactions described in this report can be found in the Issuer's and the Reporting Person's previous filings with the Commission.

F2 · balance_after: On June 6, 2024, the Reporting Person exercised 377,865 warrants at an exercise price of $13.20 per warrant (the "Original Warrants"), representing one-third of the of the Original Warrants, which were issued to the Reporting Person in connection with a warrant dividend effected on March 18, 2024, Upon such exercise, the Reporting Person was issued 377,865 shares of the Issuer's common stock and 377,865 new warrants to purchase the Issuer's common stock at an exercise price of $18.00 (the "June Warrants"). The remaining 755,728 Original Warrants were surrendered in connection with the November Agreement described in footnote 3 below. The June Warrants expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). Prior to their surrender, the Original Warrants also had an expiration date of March 26, 2028.

SEC source: 0001493152-24-022200 · ownership.xml · nonDerivative · entry 2

Bailey Gregory · CIK 0001329505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,206

SEC source: 0001493152-24-022200 · ownership.xml · nonDerivative · entry 1

Bailey Gregory · CIK 0001329505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,001

SEC source: 0001493152-24-021786 · ownership.xml · nonDerivative · entry 1

Bailey Gregory · CIK 0001329505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,828

SEC source: 0001493152-24-021358 · ownership.xml · nonDerivative · entry 2

Bailey Gregory · CIK 0001329505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,809

SEC source: 0001493152-24-021176 · ownership.xml · nonDerivative · entry 4

MINTZ STEVEN · CIK 0002008741 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 9,900

SEC source: 0001493152-24-021176 · ownership.xml · nonDerivative · entry 3

MINTZ STEVEN · CIK 0002008741 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 7,400

SEC source: 0001493152-24-021148 · ownership.xml · nonDerivative · entry 1

Bailey Gregory · CIK 0001329505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,522

SEC source: 0001493152-24-021358 · ownership.xml · nonDerivative · entry 1

Bailey Gregory · CIK 0001329505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,438